Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after undergoing surgery to remove the tumor. This test may also detect whether immunotherapy treatment administered after surgery has been effective or if residual bladder cancer remains. The breakthrough could significantly improve monitoring and treatment decisions for bladder cancer patients.
Bladder cancer is one of the most common cancers, with high recurrence rates even after surgical removal of tumors. Current monitoring methods, such as cystoscopy, are invasive and costly. The new non-invasive urine test offers a simpler and potentially more frequent way to track disease status. By detecting circulating tumor DNA in urine, the test can identify minimal residual disease that might not be visible on imaging or other tests.
The implications of this test are substantial. If validated in larger studies, it could allow doctors to tailor postoperative treatments more precisely. For example, patients whose urine test shows no tumor DNA after surgery might avoid unnecessary immunotherapy, while those with positive results could receive more aggressive treatment. This personalized approach could improve outcomes and reduce side effects.
As more forms of immunotherapy are developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), the ability to predict response to these treatments becomes increasingly important. Immunotherapy has revolutionized cancer care, but not all patients benefit. A simple urine test could help identify which patients are likely to respond, saving time and resources.
The research is part of a growing trend toward liquid biopsies in oncology. These tests analyze blood, urine, or other bodily fluids for cancer-related genetic material. They offer a less invasive alternative to traditional tissue biopsies and can be repeated more easily to monitor disease over time. The urine test for bladder cancer is particularly promising because urine is readily available and contains high concentrations of tumor DNA from the urinary tract.
The development was reported by BioMedWire, a specialized communications platform focusing on biotechnology and life sciences. The wire service is part of the Dynamic Brand Portfolio @IBN, which provides access to a network of wire solutions, article syndication to over 5,000 outlets, and social media distribution. For more information on the terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
While the test is not yet clinically available, the findings represent a significant step forward in bladder cancer management. Further studies are needed to confirm the test's accuracy and utility in diverse patient populations. If successful, it could become a standard tool in oncology clinics, improving the quality of life and survival for bladder cancer patients.
